The Pancreatic Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Pancreatic Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pancreatic Diseases. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pancreatic Diseases and features dormant and discontinued products.
GlobalData tracks 48 drugs in development for Pancreatic Diseases by 42 companies/universities/institutes. The top development phase for Pancreatic Diseases is preclinical with 23 drugs in that stage. The Pancreatic Diseases pipeline has 41 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Pancreatic Diseases pipeline products market are: CalciMedica, Daewoong Pharmaceutical and Cypralis.
The key targets in the Pancreatic Diseases pipeline products market include Lipase, Amylase, and Calcium Release Activated Calcium Channel Protein 1.
The key mechanisms of action in the Pancreatic Diseases pipeline product include Lipase Replacement with four drugs in Phase I. The Pancreatic Diseases pipeline products include six routes of administration with the top ROA being Oral and nine key molecule types in the Pancreatic Diseases pipeline products market including Small Molecule, and Cell Therapy.
Pancreatic Diseases overview
Pancreatic diseases encompass a range of conditions that affect the pancreas, a vital organ located behind the stomach. The pancreas plays a crucial role in digestion and hormone regulation by producing enzymes for digestion and hormones like insulin and glucagon that regulate blood sugar levels.
For a complete picture of Pancreatic Diseases’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
